Lexicon Pharmaceuticals Reports $14.2M Revenue in Q3 2025, Driven by Novo Nordisk Licensing Agreement

Lexicon Pharmaceuticals, Inc. reported a significant increase in revenue for the third quarter of 2025, with total revenues reaching $14.2 million, compared to $1.8 million in the same period of 2024. This growth was primarily driven by licensing revenue of $13.2 million from a recent agreement with Novo Nordisk for the development of LX9851, a drug candidate for obesity and cardiometabolic disorders. For the nine months ending September 30, 2025, total revenues were $44.3 million, a substantial rise from $4.5 million in the prior year. Despite this revenue growth, the company reported a net loss of $12.8 million, or $0.04 per share, which is an improvement from a net loss of $64.8 million, or $0.18 per share, in the same quarter last year.

In terms of operational changes, Lexicon's total operating expenses decreased significantly to $26.4 million for the third quarter of 2025, down from $65.4 million in the same quarter of 2024. This reduction was largely attributed to a decrease in selling, general, and administrative expenses, which fell to $7.6 million from $39.6 million, reflecting a strategic restructuring that reduced headcount and associated costs. Research and development expenses also decreased to $18.8 million from $25.8 million, indicating a shift in focus and resource allocation within the company.

Lexicon's financial position showed a decline in total assets, which decreased to $205.9 million as of September 30, 2025, down from $298.4 million at the end of 2024. The company's cash and cash equivalents also fell to $49.7 million from $66.7 million, while short-term investments decreased to $66.3 million from $171.3 million. The company’s accumulated deficit increased to approximately $2.0 billion, reflecting ongoing investments in research and development and operational costs.

Strategically, Lexicon has made significant moves, including the licensing agreement with Novo Nordisk, which includes potential milestone payments totaling up to $485 million and royalties on future sales. The company is also advancing its drug candidates, including pilavapadin for neuropathic pain and continuing efforts to commercialize INPEFA (sotagliflozin) for heart failure and type 2 diabetes. The company has indicated that it expects to continue incurring substantial research and development costs, which will require generating higher revenues to achieve profitability.

Looking ahead, Lexicon anticipates that its current cash and investment balances, along with expected revenues from collaborations, will be sufficient to fund operations for at least the next 12 months. However, the company acknowledges that if cash generated from operations is insufficient, it may need to seek additional financing through collaborations or equity sales, which could dilute existing shareholders. The company remains focused on its strategic goals and the successful development of its drug candidates as it navigates the complexities of the biopharmaceutical landscape.